Navigation Links
Southampton scientists begin Phase II patient trial for new asthma treatment
Date:4/8/2010

Scientists from the University of Southampton and Synairgen Research Ltd, a respiratory drug development company spun out from the University, have begun a Phase II study into the effectiveness of the drug interferon beta for asthma patients.

An increase in the frequency of asthma attacks (also known as 'exacerbations') is commonly triggered by cold or flu viruses because the lungs of patients with the condition are unable to mount the strong immune response that normally protects healthy airways.

When the infection spreads from the nose to the lungs it also causes inflammation which leads to such exacerbations.

A successful treatment to prevent virus-triggered asthma exacerbations would reduce the number of asthma patients suffering increased frequency of attacks and subsequently potentially life-threatening deterioration of lung function, thereby greatly reducing emergency admissions to hospital.

Professor Ratko Djukanovic, a clinical respiratory specialist at the University's School of Medicine and Southampton University Hospitals NHS Trust and Director of the Southampton Respiratory Biomedical Research Unit, explains: "When common cold or flu viruses spread from the nose and throat to the chest of asthma patients, they can cause a rapid deterioration in their health. Our scientists in Southampton, led by the team of Professor Donna Davies, have found in laboratory-based tests that the lungs are able to protect themselves when the protein interferon beta is introduced.

"If the drug works as we hope it will, it could significantly improve the quality of life for these patients and lessen the number of patients admitted to hospital. However, it is important to stress that there are a number of stages before the drug could be made available to the public.

"We are particularly pleased to have been joined in this clinical trial by other lead asthma centres in the UK which have similar biomedical research units funded by the National Institute for Health Research."

Over the next 9 - 15 months, asthma patients taking part in the study who visit the Biomedical Research Unit at Southampton General Hospital will be given either interferon beta or a placebo by inhalation, when they develop cold or flu symptoms.

The results will be used to determine if inhaled interferon beta is a viable treatment for virus-triggered asthma symptoms.

Scientists have already established that the drug was well tolerated in an earlier Phase I trial in asthma patients and that anti-viral defences were activated.

Richard Marsden, CEO of Synairgen, comments: "We are delighted to be starting this pivotal study. If these tests are successful it could lead to a new treatment being on the market in four years or so. This is very important research and showcases the best of British clinical science and interaction between industry and academic researchers."

Once the study has begun in Southampton, it will be extended to other clinical trial sites around the UK.


'/>"/>

Contact: Sophie Docker
S.Docker@soton.ac.uk
44-023-805-98933
University of Southampton
Source:Eurekalert

Related medicine news :

1. Scientists find out why living things are the size they are -- and none other
2. Scientists: Soccer improves health, fitness and social abilities
3. Pan-Asian hub for life scientists to open in Suzhou, China, on Monday, April 6
4. Scientists Find Clues to How the Body Fights Off HIV
5. Caltech scientists uncover structure of key protein in common HIV subgroup
6. Start spreading the news: NYU scientists find therapeutic target to stop cancer metastases
7. Scientists Tweak Subjects Brains to Alter Their Moral Choices
8. Scientists in hot pursuit of first new drug for global killer in 50 years
9. Top Scientists Explore the Origin of Life in Annual Lasker Lecture at Scripps Research Institute Florida Campus
10. Anti-obesity drugs unlikely to provide lasting benefit according to scientists
11. University of Michigan scientists identify chemical in bananas as potent inhibitor of HIV infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: